Winan van Houdt: The vital role of the surgeon in TIL treatment for metastatic melanoma
Winan van Houdt, Surgical Oncologist at Antoni van Leeuwenhoek, shared a post on LinkedIn:
“Discussing the vital role of the surgeon in TIL (tumor infiltrating lymphocytes) treatment for metastatic melanoma, at our symposium for patients and the general public in The Netherlands Cancer Institute / Antoni van Leeuwenhoek ziekenhuis.
TIL treatment always starts with an operation, and this new revolutionary treatment option leads to new questions and challenges for surgical oncologists treating melanoma and other cancers.
After completing the first academic randomized controlled trial comparing TIL treatment to ipilimumab (mostly after failing anti-PD1 treatment), TIL is now conditionally approved as standard of care in our institution, thanks to the leadership of John Haanen and hard work from Maartje Rohaan and many others.
The symposium was organized since the TIL program won the patient impact award for most revolutionary new multi-disciplinary innovation in our hospital.”
Winan van Houdt is a surgical oncologist at Antoni van Leeuwenhoek, specializing inrare cancers such as GIST, soft tissue sarcomas (retroperitoneal, intra-abdominal, and extremity), melanoma, desmoid tumors, and non-melanoma skin cancers. He serves as the Program Coordinator for Rare Cancers at the Netherlands Cancer Institute andchairs the Soft Tissue and Bone Sarcoma Group (STBSG) at the EORTC. Van Houdt is also a member of the Scientific Steering Committee for the Sarcoma Track at ESMO 2024.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023